We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

163 hedge funds and large institutions have $1.01B invested in Nurix Therapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 43 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

895% more call options, than puts

Call options by funds: $1.72M | Put options by funds: $173K

60% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 43

4.37% more ownership

Funds ownership: 111.48% → 115.85% (+4.4%)

0% more capital invested

Capital invested by funds: $1.01B → $1.01B (+$825K)

4% less funds holding

Funds holding: 170 → 163 (-7)

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
163
Holders Change
-7
Holders Change %
-4.12%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
23
Increased
69
Reduced
43
Closed
30
Calls
$1.72M
Puts
$173K
Net Calls
+$1.55M
Net Calls Change
+$867K

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$37.7M
2
UBS Group
UBS Group
Switzerland
+$9.9M
3
VPC
Vestal Point Capital
New York
+$9.45M
4
PA
Perceptive Advisors
New York
+$8.64M
5
Morgan Stanley
Morgan Stanley
New York
+$7.57M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$18.6M
2
RCM
RA Capital Management
Massachusetts
-$15.8M
3
BlackRock
BlackRock
New York
-$12.7M
4
DCM
Driehaus Capital Management
Illinois
-$8.51M
5
SC
Samlyn Capital
New York
-$6.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$10.6M +$574K +53,159 +6%
Northern Trust
27
Northern Trust
Illinois
$7.44M -$506K -46,784 -7%
Charles Schwab
28
Charles Schwab
California
$6.92M +$271K +25,061 +4%
Goldman Sachs
29
Goldman Sachs
New York
$6.66M +$833K +77,048 +15%
Artisan Partners
30
Artisan Partners
Wisconsin
$6.61M -$625K -57,860 -9%
WA
31
Wasatch Advisors
Utah
$5.55M -$895K -82,861 -15%
Dimensional Fund Advisors
32
Dimensional Fund Advisors
Texas
$4.87M -$1.6M -148,241 -26%
PSC
33
Patient Square Capital
California
$4.7M -$378K -35,000 -8%
Voloridge Investment Management
34
Voloridge Investment Management
Florida
$4.27M +$2.12M +195,730 +109%
Deutsche Bank
35
Deutsche Bank
Germany
$4.2M -$122K -11,270 -3%
Qube Research & Technologies (QRT)
36
Qube Research & Technologies (QRT)
United Kingdom
$4.06M +$670K +61,995 +21%
Bank of America
37
Bank of America
North Carolina
$3.73M -$951K -87,975 -21%
ACH
38
ArrowMark Colorado Holdings
Colorado
$3.59M – – –
IHAM
39
Integral Health Asset Management
New York
$3.53M +$378K +35,000 +13%
Bessemer Group
40
Bessemer Group
New Jersey
$3.48M – – –
Two Sigma Advisers
41
Two Sigma Advisers
New York
$3.24M +$964K +89,200 +46%
Handelsbanken Fonder
42
Handelsbanken Fonder
Sweden
$3.19M +$3.03M +280,000 New
CS
43
Candriam SCA
Luxembourg
$2.99M -$3.53M -326,547 -55%
KCM
44
Kennedy Capital Management
Missouri
$2.94M +$570K +52,716 +26%
Barclays
45
Barclays
United Kingdom
$2.9M +$1.19M +110,095 +76%
UBS AM
46
UBS AM
Illinois
$2.64M +$784K +72,525 +45%
Ensign Peak Advisors
47
Ensign Peak Advisors
Utah
$2.63M – – –
WFA
48
WestHill Financial Advisors
California
$2.6M – – –
PHP
49
Parkman Healthcare Partners
Connecticut
$2.6M -$1.32M -122,149 -35%
Bank of New York Mellon
50
Bank of New York Mellon
New York
$2.55M +$206K +19,047 +9%
1
2
3 4 5

NRIX Hedge Fund Activity: Q2 2025 in Review

163 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2025, worth a combined $1.01B — up 0.08% from $1.01B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of NRIX and 23 opened new positions — a net loss of 7 holders — while 43 trimmed existing stakes and 69 added.

The largest buyer was Point72 Asset Management, adding an estimated $37.7M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.

  • 163 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2025, down from 170 in Q1 2025.
  • Funds reported $1.01B of Nurix Therapeutics stock for Q2 2025, up 0.08% quarter-over-quarter.
  • 23 funds opened new Nurix Therapeutics positions in Q2 2025 and 30 closed out, a net change of -7 holders.
  • The largest Nurix Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $37.7M added.
  • The largest Nurix Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $18.6M sold.

Based on aggregated 13F filings for Q2 2025.